STATEN ISLAND, New York, Sept. 11, 2026 (GLOBE NEWSWIRE) — Coffee Holding Co., Inc. (Nasdaq: JVA) (the “Company,” “our” or “we”) announced its operating results for the fiscal quarter ended July 31, 2026.

Net Sales. Net sales totaled $21,686,262 for the three months ended July 31, 2026, a decrease of $2,224,252, or 9.3% , from $23,910,514 for the three months ended July 31, 2025. The decrease in net sales was primarily attributable to the sustained decline in green coffee prices that began in late January and continued throughout most of the quarter. In response to these market conditions, the Company reduced prices and initiated promotional activity for its wholesale roasted coffee customers. In addition, the Company charged lower prices to its wholesale green coffee customers due to the decline in prevailing coffee market prices during the quarter.

Cost of Sales. Cost of sales for the three months ended July 31, 2026, was $16,262,131, or 75.0% of net sales, as compared to $21,655,486, or 90.6% of net sales, for the three ended July 31, 2025. Cost of sales consists primarily of the cost of green coffee and packaging materials and realized and unrealized gains or losses on hedging activity. While cost of sales decreased due to lower sales volume, cost of sales as a percentage of net sales also decreased, primarily due to a favorable inventory position acquired during the first half of the fiscal year when coffee prices declined significantly, tariff refunds recognized during the current period, and a net gain on trading activity during the current period compared to a net loss on trading activity in the comparative period.

Gross Profit. Gross profit for the three months ended July 31, 2026, was $5,424,131, an increase of $3,169,103 from $2,255,028 for the three months ended July 31, 2025. Gross profit as a percentage of net sales was 25.0% for the three months ended July 31, 2026, compared to 9.4% for the three months ended July 31, 2025. The increase in gross profit was primarily attributable to a favorable inventory position, tariff refunds, and a net gain on trading activity during the current period, as discussed above.

Operating Expenses. Total operating expenses decreased by $250,378 to $3,099,801 for the three months ended July 31, 2026, from $3,350,179 for the three months ended July 31, 2025. Selling and administrative expenses decreased from $3,166,764 for the three months ended July 31, 2025, to $2,899,193 for the three months ended July 31, 2026. Operating expenses decreased slightly compared to the prior-year period but remained generally consistent with historical levels.

Net Income (Loss). We had net income of $1,993,438 or $0.35 per share basic and diluted, for the three months ended July 31, 2026, compared to net loss of $1,205,413, or $0.21 per share basic and diluted, for the three months ended July 31, 2025. The change in net income was due to our results of operations as described above.

“In what can only be described as the most volatile three months in the history of the coffee market, with the price of green coffee trading in a $1.00/per lb. trading range with daily price fluctuations reaching an unprecedented $.50/lb., we are pleased to report our shareholders that we had net sales of approximately $21.7 million and earnings of $0.35 a share. Although revenues were comparable to those achieved in fiscal 2025, our profitability was greatly improved as a result of a combination of supporting fundamentals provided a strong tailwind during the reporting period. We were fortunate to have capitalized on the lower green physical coffee market during the first half of calendar 2026 which allowed for the record gross margins we achieved during fiscal Q3 2026.

The decision not to charge most wholesale roasted customers tariffs during 2025 proved to be the correct one as we retained 100% of our roasted customer base and maintained our historical profit margins throughout the last several quarters. Now, with tariffs being slowly refunded, we are reaping the rewards for our earlier decisions as the tariff refunds received during the quarter contributed approximately $.06 a share to our earnings and we expect additional refunds to enhance earnings over the next two quarters. Overall, with the continued volatility in the green coffee market showing no clear signs of abating, and the major leading national brands showing no indication of price decreases, as well as significant new business that we have recently secured, we believe we are well positioned moving through the end of calendar 2026 into calendar 2027 to grow our revenue levels, gross margins and our profitability,” concluded Mr. Andrew Gordon, Chief Executive Officer of the Company.

About Coffee Holding

Founded in 1971, Coffee Holding Co., Inc. (NASDAQ: JVA) is a leading integrated wholesale coffee roaster and dealer in the United States and one of the few coffee companies that offers a broad array of coffee products across the entire spectrum of consumer tastes, preferences and price points. Coffee Holding’s product offerings consist of eight proprietary brands, each targeting a different segment of the consumer coffee market as well as roasting and blending coffees for major wholesalers and retailers throughout the United States who want to have products under their own names to compete with national brands. In addition to selling roasted coffee, Coffee Holding also imports green coffee beans from around the world, which it resells to smaller regional roasters and coffee shops around the United States and Canada.

Forward looking statements

Any statements that are not historical facts contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the Company’s outlook on revenue and profitability growth. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. We have based these forward-looking statements upon information available to management as of the date of this release and management’s expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Such statements may involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, hedging activities, the effect of economic conditions (including tariffs), intellectual property rights, the outcome of competitive products, the results of financing efforts, the ability to complete transactions and other risks and uncertainties described in the “Risk Factors” section of documents filed by the Company from time to time with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made.

Company Contact

Coffee Holding Co., Inc.
Andrew Gordon
President & CEO
(718) 832-0800

COFFEE HOLDING CO., INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

    July 31, 2026     October 31, 2025  
    (Unaudited)        
ASSETS                
CURRENT ASSETS:                
Cash and cash equivalents   $ 2,915,888     $ 701,872  
Accounts receivable, net of allowances of $313,000 for July 31, 2026 and October 31, 2025.     8,985,454       12,093,251  
Inventories     19,480,689       20,446,481  
Due from broker     1,556,868       1,424,036  
Prepaid expenses and other current assets     722,376       594,360  
Prepaid and refundable income taxes     —       180,916  
TOTAL CURRENT ASSETS     33,661,275       35,440,916  
                 
Building, machinery, and equipment, net     3,187,735       3,463,072  
Customer list and relationships, net of accumulated amortization of $330,625 and $316,250 for July 31, 2026 and October 31, 2025, respectively     109,375       123,750  
Trademarks and tradenames     327,000       327,000  
Equity investments     889,651       39,651  
Right of use assets     1,694,679       2,084,175  
Deferred income tax assets – net     180,282       229,899  
Deposits and other assets     134,642       339,909  
TOTAL ASSETS     40,184,639       42,048,372  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
CURRENT LIABILITIES:                
Accounts payable and accrued expenses     4,881,856       5,641,836  
Line of credit     2,150,000       6,050,000  
Due to broker     179,915       303,813  
Lease liabilities – current portion     912,755       811,975  
TOTAL CURRENT LIABILITIES     8,124,526       12,807,624  
                 
Lease liabilities – long term     1,042,673       1,530,096  
Deferred compensation payable     –       129,646  
TOTAL LIABILITIES     9,167,199       14,467,366  
                 
Commitments and Contingencies (Note 10)     –        –   
                 
STOCKHOLDERS’ EQUITY:                
Common stock, par value $.001 per share; 30,000,000 shares authorized, 6,633,930 shares issued for July 31, 2026 and October 31, 2025; 5,708,599 shares outstanding for July 31, 2026 and October 31, 2025     6,634       6,634  
Additional paid-in capital     19,094,618       19,094,618  
Retained earnings     16,549,748       13,113,314  
Less: common stock held in treasury, at cost; 925,331 shares at July 31, 2026 and October 31, 2025     (4,633,560 )     (4,633,560 )
TOTAL STOCKHOLDERS’ EQUITY     31,017,440       27,581,006  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 40,184,639     $ 42,048,372  

COFFEE HOLDING CO., INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

                                 
    Nine months ended July 31,     Three months ended July 31,  
    2026     2025 (revised)     2026     2025 (revised)  
NET SALES   $ 69,378,258     $ 68,535,860     $ 21,686,262     $ 23,910,514  
COST OF SALES     54,342,122       57,446,245       16,262,131       21,655,486  
GROSS PROFIT     15,036,136       11,089,615       5,424,131       2,255,028  
                                 
OPERATING EXPENSES:                                
Selling and administrative     9,382,355       9,067,134       2,899,193       3,166,764  
Officers’ salaries     610,214       637,986       200,608       183,415  
TOTAL     9,992,569       9,705,120       3,099,801       3,350,179  
                                 
INCOME (LOSS) FROM OPERATIONS     5,043,567       1,384,495       2,324,330       (1,095,151 )
                                 
OTHER INCOME (EXPENSE):                                
Interest income     21       28       7       5  
Interest expense     (143,180 )     (141,905 )     (37,816 )     (92,683 )
Other income     –       29       –       –  
TOTAL     (143,159 )     (141,848 )     (37,809 )     (92,678 )
                                 
INCOME BEFORE INCOME TAX     4,900,408       1,242,647       2,286,521       (1,187,829 )
Income Tax Provision     996,161       650,749       293,083       17,584  
NET INCOME (LOSS)   $ 3,904,247     $ 591,898     $ 1,993,438     $ (1,205,413 )
                                 
Basic and diluted income (loss) per share   $ 0.68     $ 0.10     $ 0.35     $ (0.21 )
Weighted average common shares outstanding:                                
Basic and diluted     5,708,599       5,708,599       5,708,599       5,708,599  

COFFEE HOLDING CO., INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
THREE AND NINE MONTHS ENDED JULY 31, 2026 AND 2025
(UNAUDITED)

    Common Stock     Treasury Stock     Additional Paid-in     Retained        
    Shares     Amount     Shares     Amount     Capital     Earnings     Total  
Balance, October 31, 2024   $ 5,708,599     $ 6,634     $ 925,331     $ (4,633,560 )   $ 19,094,618     $ 11,709,875     $ 26,177,567  
Net income     –       –       –       –       –       1,153,256       1,153,256  
Balance, January 31, 2025     5,708,599       6,634       925,331       (4,633,560 )     19,094,618       12,863,131       27,330,823  
Net income     –       –       –       –       –       644,055       644,055  
Balance, April 30, 2025     5,708,599       6,634       925,331       (4,633,560 )     19,094,618       13,507,186       27,974,878  
Net loss     –       –       –       –       –       (1,205,413 )     (1,205,413 )
Balance, July 31, 2025     5,708,599       6,634       925,331       (4,633,560 )     19,094,618       12,301,773       26,769,465  
                                                         
Balance, October 31, 2025     5,708,599       6,634       925,331       (4,633,560 )     19,094,618       13,113,314       27,581,006  
Dividend declared at $0.08 per common share outstanding     –       –       –       –       –       (467,813 )     (467,813 )
Net income     –       –       –       –       –       1,648,320       1,648,320  
Balance, January 31, 2026     5,708,599       6,634       925,331       (4,633,560 )     19,094,618       14,293,821       28,761,513  
Net income     –       –       –       –       –       262,489       262,489  
Balance, April 30, 2026     5,708,599       6,634       925,331       (4,633,560 )     19,094,618       14,556,310       29,024,002  
Net income     –       –       –       –       –       1,993,438       1,993,438  
Balance, July 31, 2026   $ 5,708,599     $ 6,634     $ 925,331     $ (4,633,560 )   $ 19,094,618     $ 16,549,748     $ 31,017,440  

COFFEE HOLDING CO., INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

    2026     2025  
    Nine months ended July 31,  
    2026     2025  
OPERATING ACTIVITIES:                
Net income   $ 3,904,247     $ 591,898  
Adjustments to reconcile net income to net cash provided by (used in) operating activities:                
Depreciation and amortization     653,250       492,379  
Realized and unrealized gains, net     (781,730 )     (1,862,877 )
Amortization of right-of-use asset     508,854       583,643  
Bad debt expense     50,000       –  
Deferred income taxes (benefit)     49,617       (315,709 )
Changes in operating assets and liabilities:                
Accounts receivable     3,057,797       (185,622 )
Inventories     965,792       (5,711,012 )
Prepaid expenses and other current assets     (128,016 )     (664,433 )
Prepaid and refundable income taxes     180,916       285,439  
Deposits and other assets     205,267       (408,978 )
Accounts payable and accrued expense     (759,980 )     2,339,316  
Change in lease liabilities     (506,001 )     (549,346 )
Change in due/from broker     525,000       –  
Deferred compensation payable     (129,646 )     8,586  
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES     7,795,367       (5,396,716 )
                 
INVESTING ACTIVITIES:                
Acquisition of Second Empire     –       (800,000 )
Purchase of investment     (850,000 )     –  
Cash paid for leasehold improvements     (280,834 )     (375,286 )
Purchases of building, machinery and equipment     (82,704 )     (79,249 )
NET CASH USED IN INVESTING ACTIVITIES     (1,213,538 )     (1,254,535 )
                 
FINANCING ACTIVITIES:                
Payment of dividends     (467,813 )     –  
Proceeds from bank line of credit     –       7,750,000  
Principal payments under bank line of credit     (3,900,000 )     (1,500,000 )
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES     (4,367,813 )     6,250,000  
                 
NET CHANGE IN CASH AND CASH EQUIVALENTS     2,214,016       (401,251 )
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR     701,872       1,381,023  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 2,915,888     $ 979,772  
                 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW DATA:                
Cash paid for income taxes   $ –     $ –  
Interest paid   $ 171,345     $ 96,761  
                 
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:                
Initial recognition of lease right-of-use asset   $ 119,358     $ 2,113,581  
Initial recognition of lease liabilities   $ 119,358     $ 2,113,581  

The olive tree has inspired beauty for 4,000 years and now it walks the runway at New York Fashion Week

Olive_Tree_People_F97

F97 Deep Glow Hydrogel Face Mask: A waterless hydrogel mask built on olive fruit juice instead of water, with sodium hyaluronate for lasting moisture. As the essence absorbs, the mask gradually turns transparent — and skin is left feeling smoother, softer, and refreshed.
F97 Deep Glow Hydrogel Face Mask: A waterless hydrogel mask built on olive fruit juice instead of water, with sodium hyaluronate for lasting moisture. As the essence absorbs, the mask gradually turns transparent — and skin is left feeling smoother, softer, and refreshed.

Olive_Tree_People_F96

F96 Olive Glow Eye Patches | Waterless hydrogel eye patches that combine olive fruit juice, naturally rich in antioxidants, with sodium hyaluronate for lasting hydration — leaving the delicate eye area feeling smoother, softer, and revitalized.
F96 Olive Glow Eye Patches | Waterless hydrogel eye patches that combine olive fruit juice, naturally rich in antioxidants, with sodium hyaluronate for lasting hydration — leaving the delicate eye area feeling smoother, softer, and revitalized.

SANTA MONICA, CA, Sept. 11, 2026 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTCID: OLVI) today announced that its OLIVE TREE PEOPLE subsidiary and the Olive Rose makeup brand are joining forces with internationally acclaimed fashion designer Bibhu Mohapatra for his New York Fashion Week show in the Grand Ballroom of The Pierre Hotel in Manhattan.

For more than 4,000 years, the olive tree has been one of humanity’s most enduring symbols of beauty, vitality and transformation.

This Monday, it becomes couture.

Bibhu Mohapatra is transforming the world of Olive Tree People and Olive Rose into an exclusive couture creation – while than 20 makeup artists and an unprecedented front-row beauty ritual take over New York Fashion Week.

At the heart of the collaboration will be the unveiling of a one-of-one Olive Rose gown, created by Mohapatra exclusively for Olive Tree People, Oliveda and Olive Rose.

The design brings together two worlds: the olive tree, represented through its iconic leaves, and Olive Rose, expressed through the beauty and sensuality of the rose.

It is not simply a dress featuring the symbols of two brands.

It is the story of an ancient tree transformed into modern couture.

The olive tree becomes fashion.
The rose becomes movement.
And a 4,000-year-old beauty secret walks the runway.

“For thousands of years, the olive tree has represented beauty, strength and life. Bibhu did not simply place olive leaves and roses on a dress. He translated the soul of our world into couture. On Monday, the olive tree will no longer stand beside the runway. It will walk it,” said Thomas Lommel, Founder of Olive Tree People.

MORE THAN A BEAUTY PARTNERSHIP

Behind the scenes, Olive Tree People and Olive Rose will lead the beauty experience for the show.

A team of more than 20 makeup artists, under the direction of Olive Rose Chief Celebrity Makeup Artist Luis Casco, will create the runway beauty looks and prepare the models and invited VIP guests.

Olive Rose first appeared at New York Fashion Week last year, where it was celebrated as the world’s only makeup line based on Hydroxytyrosol.

This year, Olive Rose returns on an entirely new scale – not only on the faces of the models, but as the inspiration for an exclusive Bibhu Mohapatra couture creation and an unforgettable beauty experience extending from backstage to the front row.

THE FRONT ROW WILL BECOME PART OF THE SHOW

In keeping with an Olive Tree People tradition, guests will be offered individually hand-braided olive crowns—an ancient symbol of beauty, peace, strength and victory.

But this year, the tradition will be taken one step further.

To celebrate the launch of the new Olive Tree People Hydroxytyrosol Hydrogel Face Masks and Eye Patches, front-row guests will be invited to participate in a choreographed beauty ritual before the runway show begins.

Wearing the new Hydroxytyrosol treatments together with their olive crowns, the most photographed guests in the room will create one of New York Fashion Week’s most unexpected images:

An entire front row crowned by the olive tree—with their faces beneath Hydroxytyrosol masks.

For a few extraordinary minutes, the front row will stop observing beauty and begin experiencing it.

No hiding the treatment behind a bathroom door.
No pretending beauty happens effortlessly.
No waiting until Fashion Week is over to take care of the skin.

Instead, skincare will take the best seat in fashion.

FROM BACKSTAGE TO THE RUNWAY—AND ONTO THE SKIN

The collaboration connects every part of the Olive Tree People universe.

The olive tree inspires the dress.
Olive Rose creates the color.
Hydroxytyrosol touches the skin.
The olive crowns transform the guests.
And Bibhu Mohapatra brings the entire story to life through fashion.

It is a meeting of ancient beauty intelligence and modern creative expression—inside one of Manhattan’s most iconic ballrooms.

One ancient tree.
One exclusive couture creation.
More than 20 makeup artists.
And a front row New York Fashion Week will not forget.

ABOUT OLIVE TREE PEOPLE
Olive Tree People is a pioneer and leading force in waterless beauty. Instead of using the conventional water phase found in most skincare products, the company replaces water with its proprietary olive leaf cell elixir and combines it with powerful olive-tree ingredients, including Hydroxytyrosol.

Founded by olive tree farmer Thomas Lommel, Olive Tree People develops skincare, beauty and holistic experiences based on more than 20 years of work with mountain olive trees and the principles of Olive Tree Therapy.

ABOUT OLIVE ROSE
Olive Rose is the color cosmetics world of Olive Tree People and Oliveda. Introduced at New York Fashion Week as the world’s only makeup line based on Hydroxytyrosol, Olive Rose brings together high-performance color, skincare intelligence and the transformative beauty of the olive tree.

About Oliveda International, Inc. 
Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG, Oliveda Deutschland GmbH, and Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel. The companies possess over 20 years of experience in management and organic certification growing mountain olive trees; in the extraction of first-class, internationally award-winning extra virgin olive oils; the extraction of hydroxytyrosol; and the production and distribution of cosmetic and holistic waterless products related to the olive tree.  Lommel is the inventor of the “Olive Tree Therapy 10 Years in 14 Days” as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on the olive leaf and hydroxytyrosol.  In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

In addition to the registered beauty brands, Oliveda and LA Dope, as well as the brands Olive Rose, OLIVE re:connected to Nature, The Intuition of Nature, Olive Mush, Baby & Mom, and Is That Matty?, Lommel is the region’s largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees. With his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.

The company’s direct-to-consumer network includes tens of thousands of Waterless Beauty Consultants in North America and Europe. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand’s treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine.  Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper’s Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute.  Gigi Hadid and many other celebrities are already Oliveda fans and support its success.  Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com

Forward-Looking Statements
This press release may contain statements, estimates or projections that constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company’s historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made.  The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.

Attachments

CONTACT: OLVI Investor Relations
619-202-7456
olvi@advanceprgroup.com

ProVen VCT plc 
Issue of Equity
11 September 2026

The Directors of ProVen VCT plc announce an allotment on 11 September 2026 of ordinary shares of 10p each (“Ordinary Shares”) pursuant to the offer for subscription that opened on 17 November 2025. The allotment also included a small number of shares issued to existing shareholders in satisfaction of commission payments due to their brokers.

1,141,293 Ordinary Shares were allotted at an average price of 61.41p, based on the latest net asset value of 59.5p, being the net asset value per Ordinary Share as at 31 May 2026 adjusted for the dividend of 1.6p paid on 14 August 2026. 7,243 Ordinary Shares were allotted at the same price in connection with commission payments. The total Ordinary Shares allotted were 1,148,536.

Application for the shares to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange’s market for listed securities will be made shortly.

These shares will rank pari passu with existing Ordinary Shares.

Following this allotment, the issued share capital and total voting rights of ProVen VCT plc is 298,575,634 Ordinary Shares.

Beringea LLP
Company Secretary
Telephone 020 7845 7820

-End-

ProVen Growth and Income VCT plc
Issue of Equity
11 September 2026

The Directors of ProVen Growth and Income VCT plc announce an allotment on 11 September 2026 of ordinary shares of 1.6187p each (“Ordinary Shares”) pursuant to the offer for subscription that opened on 17 November 2025. The allotment also included a small number of shares issued to existing shareholders in satisfaction of commission payments due to their brokers.

709,540 Ordinary Shares were allotted at an average price of 48.09p, based on the latest net asset value of 46.3p, being the net asset value per Ordinary Share as at 31 May 2026 adjusted for the dividend of 1.3p paid on 14 August 2026. 3,463 Ordinary Shares were allotted at the same price in connection with commission payments. The total Ordinary Shares allotted were 713,003.

Application for the shares to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange’s market for listed securities will be made shortly.

These shares will rank pari passu with existing Ordinary Shares.

Following this allotment, the issued share capital and total voting rights of the ProVen Growth and Income VCT plc is 328,019,357 Ordinary Shares.

Beringea LLP
Company Secretary
Telephone 020 7845 7820

-End-

Reference is made to the stock exchange notice sent Thursday 10 September 2026.
SalMar ASA (rated BBB by Nordic Credit Rating) has today, 11 September 2026, completed an extension of NOK 250 million on its commercial paper NO0013770180, coupon 5,37% p.a., settlement date 15 September 2026 and maturity date 15 September 2027. Following the extension, the total outstanding volume of the commercial paper will amount to NOK 500 million.

Manager: DNB Carnegie

This information is subject to the disclosure requirements stipulated in section 5-12 of the Norwegian Securities Trading Act.

FORESIGHT ENTERPRISE VCT PLC
LEI: 213800MWJNR3WZZ3ZP42

INTENTION TO FUNDRAISE
11 SEPTEMBER 2026

The Board of Foresight Enterprise VCT plc is pleased to announce that the Company intends to open an offer for subscription of new ordinary shares of up to £20 million later this year (the ‘Offer’). An Offer document will be available in due course.

For further information, please contact:

Company Secretary:
Foresight Group LLP
Contact: Stephen Thayer Tel: 0203 667 8100

Investor Relations:
Foresight Group LLP
Contact: Andrew James Tel: 0203 667 8181

The Appointments Add Experience Across Technology, Food and Beverage, Franchising, Branding, and Logistics

BREA, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Reborn Coffee Inc. (Nasdaq: REBN) (the “Company”), a leader in the specialty coffee market, today announced the appointment of Edward Park and James Lim to its Board of Directors (the “Board”), effective September 3, 2026.

Mr. Park and Mr. Lim were appointed to fill vacancies on the Board following the Board’s decision to increase its authorized size from seven to eight members. Each director will serve until the Company’s next annual meeting of stockholders or until his successor is duly appointed and qualified, subject to earlier death, resignation, retirement, disqualification, removal from office or other cause.

The appointments broaden the range of operating and industry experience represented on the Board. Mr. Park brings more than 26 years of experience spanning advanced technology and international business management. His background includes senior and leadership roles in the computer and networking industries, including point-of-sale systems, fiber-optic communications, and high-speed networking. Mr. Park also has experience assisting with the development and management of franchise and restaurant businesses. He has served as chief executive officer of multiple companies. Earlier in his career, he held senior positions with Samsung Electronics Co. Ltd, Novell Korea, and Harmonic Inc. Mr. Park holds a Master of Electrical Engineering degree from Seoul National University and has received notable recognition for technology and sales performance during his career.

Mr. Lim brings more than 15 years of experience in coffee distribution, roasting, and branding. After graduating from Kookmin University with a degree in Education, he began his career in the coffee industry with a coffee distribution and roasting company. He subsequently spent more than ten years at Hollys Coffee in Seoul, South Korea, where his responsibilities included coffee distribution, roasting, and branding, followed by approximately five years at Caffe Bene where he served as General Manager. Mr. Lim currently works in the logistics industry in the United States.

Together, the appointments add perspectives spanning brand development, franchise operations, logistics, technology, and international business management. The Company believes this combination of experience will provide additional depth to the Board as it oversees Reborn Coffee’s operations and long-term business priorities.

Neither Mr. Park nor Mr. Lim has been appointed to a committee of the Board at this time, and neither will receive compensation for service as a director.

About Reborn Coffee

Reborn Coffee, Inc. (NASDAQ: REBN) is a California-based specialty coffee retailer focused on delivering high-quality, handcrafted coffee experiences. With a growing global footprint and a dedication to innovation, Reborn is redefining the coffeehouse model through its premium products and technology-forward initiatives.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission (“SEC”) including our Form 10-K for the year ended December 31, 2025, which can be found on the SEC’s website at www.sec.gov. Such risks, uncertainties, and other factors include, but are not limited to, the Company’s ability to continue as a going concern, the Company’s ability to successfully open additional locations, the Company’s ability to expand its business both within and outside of California (including as it relates to increasing sales and growing Average Unit Volumes at our existing stores), the degree of customer loyalty to our stores and products, the fluctuation of economic conditions, competition and inflation. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
REBN@mzgroup.us
949-491-8235

Company Contact:
Reborn Coffee, Inc.
ir@reborncoffee.com

New York, New York, Sept. 11, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which provides livestreaming ecommerce services, business management and information systems consulting services in China, today announced the pricing of a $6.0 million aggregate original principal amount convertible promissory note (the “Note”) to Stratosphere Capital Management Inc. (the “Purchaser”) pursuant to a Note Purchase Agreement entered into on September 9, 2026 (“Issuance Date”).

The Company estimates that the net proceeds from the offering of the Note will be approximately $6.0 million, after deducting estimated offering expenses payable by the Company.

The Note will bear interest at a rate of 8.00% per annum, which will accrue from the Issuance Date until the Note is paid in full, and is payable in cash. The Note has no fixed maturity date and the Note in full or in any portion is convertible into the Company’s Class A ordinary shares, no par value per share, at the option of the holder at any time on or after the Issuance Date. The conversion price will be equal to 80% of the lowest daily volume-weighted average price (VWAP) of the ordinary shares on the Nasdaq Capital Market during the three trading days ending on and including the applicable conversion date.

Conversions of the Note are subject to a strict beneficial ownership limitation, meaning the holder will not have the right to convert any portion of the Note if, immediately following such conversion, the holder and its affiliates would beneficially own in excess of 9.99% of the Company’s issued and outstanding ordinary shares. Additionally, the ordinary shares issuable upon conversion of the Note are subject to a Conversion Shares Registration Cap of 12,000,000 shares.

The Notes are being offered pursuant to a “shelf” registration statement on Form F-3 (File No. 333-295047), that was previously filed by the Company and became effective under the rules of the Securities and Exchange Commission (the “SEC”) on May 5, 2026. A preliminary prospectus supplement relating to the Offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. Before investing in the Offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC, which provide more information about the Company and the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Any unregistered conversion shares issued in excess of the registration cap will constitute “restricted securities” under the Securities Act of 1933, as amended, and may not be offered, sold, or otherwise transferred absent an effective registration statement or an available exemption from registration.

About Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Limited (“Antelope Enterprise”, “AEHL” or the “Company”) engages holds a 51% ownership position in Hainan Kylin Cloud Services Technology Co. Ltd (“Kylin Cloud”), which operates a livestreaming e-commerce business in China. For more information, please visit our website at https://aehltd.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, future Bitcoin market performance and developments in the Bitcoin industry, our ability to regain customers lost resulting in a decline in our revenues, the continued stable macroeconomic environment in the PRC, the consumer and technology sectors continuing to exhibit sound long-term fundamentals, our ability to continue as a going concern, our ability to raise capital to meet our capital needs, and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 6-K for the year ended March 31, 2026 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:
Antelope Enterprise Holdings Limited
Xiaoying Song, Chief Financial Officer
info@aehltd.com

WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market,” please visit: https://ibn.fm/HOCTP

Today’s multiple sclerosis (“MS”) treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control.

That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. 

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For further information, please visit the company’s website at www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

  • Access the video webcast here

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments.

The on-demand presentation is available for viewing beginning today, September 11, 2026, at 7:00 a.m. ET, and can be accessed through the Events page on the Investors section of the Company’s website (moleculin.com). 

Management will be available on-site at the conference being held September 14-16, 2026, in New York, NY to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. 

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.